Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

agilon health : Sets Date to Report Third Quarter 2021 Financial Results

10/12/2021 | 09:10am EST

agilon health will provide a preliminary 2022 membership outlook in conjunction with third quarter financial results on October 28

agilon health (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, announced that it will release its financial results for the third quarter 2021 after the market closes on Thursday, October 28, 2021, and host a conference call at 8:30 AM Eastern Time on Friday, October 29, 2021 to discuss the results.

In conjunction with the release of third quarter financial results, agilon health will provide a preliminary membership outlook for 2022, including growth expectations for Medicare Advantage members and attributed Direct Contracting beneficiaries.

The conference call and webcast can be accessed by dialing (844) 200-6205 or (646) 904-5544 for U.S. participants and + 1 (929) 526-1599 for international participants, and referencing participant code 122631, or visiting the “Events & Presentations” section of https://investors.agilonhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About agilon health
agilon health is transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients. Through our partnerships and our platform, agilon is leading the nation in creating the system we need – one built on the value of care, not the volume of fees. We honor the independence of local physicians and serve as their partners so they can be the doctors they trained to be. agilon provides the capital, data, payor relationships, executive experience and contract support that allow physician groups to take on the risk of total care for their most vulnerable patients. The result: healthier communities, and doctors who can devote the right amount of time with the patients who need it most. With rapidly growing appeal, agilon is scaled to grow and is here to help our nation’s best independent physician groups have a sustained, thriving future. Together, we are reinventing primary care. For more information about agilon health, visit www.agilonhealth.com and connect with us on Twitter, Instagram, Linked In and YouTube.

ę Business Wire 2021
All news about AGILON HEALTH, INC.
12/07AGILON HEALTH : 7 Ways Patients Experience Care Differently Under the agilon health Model
12/06AGILON HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
12/06AGILON HEALTH : Preserving Medicare Advantage
11/30AGILON HEALTH : The Many Ways agilon health is Giving Back
11/11agilon health to Participate in Wolfe Research Healthcare Conference
11/11What Military Medicine Taught This Primary Care Physician About Delivering Value-Based ..
11/03Deutsche Bank Lowers Agilon Health's Price Target to $36 From $44, Maintains Buy Rating
11/02Recent Honors Showcase agilon health Business Strength
11/01SVB Leerink Adjusts agilon health's Price Target to $35 from $37, Keeps Outperform Rati..
10/29November 2021 Investor Presentation
More news
Analyst Recommendations on AGILON HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 1 824 M - -
Net income 2021 -395 M - -
Net cash 2021 1 060 M - -
P/E ratio 2021 -23,2x
Yield 2021 -
Capitalization 9 326 M 9 326 M -
EV / Sales 2021 4,53x
EV / Sales 2022 3,21x
Nbr of Employees 550
Free-Float 98,6%
Duration : Period :
agilon health, inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILON HEALTH, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 23,69 $
Average target price 37,33 $
Spread / Average Target 57,6%
EPS Revisions
Managers and Directors
Steven J. Sell President, Chief Executive Officer & Director
Timothy S. Bensley Chief Financial Officer
Ronald A. Williams Chairman
Benjamin Kornitzer Chief Medical & Quality Officer
Girish Venkatachaliah Chief Technology Officer
Sector and Competitors